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Abstract
A recombinant adeno-associated virus serotype 2 Reference Standard Material (rAAV2 RSM) has been produced
and characterized with the purpose of providing a reference standard for particle titer, vector genome titer, and
infectious titer for AAV2 gene transfer vectors. Production and purification of the reference material were carried
out by helper virus–free transient transfection and chromatographic purification. The purified bulk material was
vialed, confirmed negative for microbial contamination, and then distributed for characterization along with
standard assay protocols and assay reagents to 16 laboratories worldwide. Using statistical transformation and
modeling of the raw data, mean titers and confidence intervals were determined for capsid particles ({X},
9.181011 particles/ml; 95% confidence interval [CI], 7.891011 to 1.051012 particles/ml), vector genomes
({X}, 3.281010 vector genomes/ml; 95% CI, 2.701010 to 4.751010 vector genomes/ml), transducing units
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({X}, 5.09108 transducing units/ml; 95% CI, 2.00108 to 9.60108 transducing units/ml), and infectious units
({X}, 4.37109 TCID50 IU/ml; 95% CI, 2.06109 to 9.26109 TCID50 IU/ml). Further analysis confirmed the
identity of the reference material as AAV2 and the purity relative to nonvector proteins as greater than 94%. One
obvious trend in the quantitative data was the degree of variation between institutions for each assay despite the
relatively tight correlation of assay results within an institution. This relatively poor degree of interlaboratory
precision and accuracy was apparent even though attempts were made to standardize the assays by providing
detailed protocols and common reagents. This is the first time that such variation between laboratories has been
thoroughly documented and the findings emphasize the need in the field for universal reference standards. The
rAAV2 RSM has been deposited with the American Type Culture Collection and is available to the scientific
community to calibrate laboratory-specific internal titer standards. Anticipated uses of the rAAV2 RSM are
discussed.
Introduction
Recombinant adeno-associated viral (rAAV) vectorsare rapidly becoming the gene delivery vehicle of choice
for gene transfer, with numerous publications describing their
use in animal models and more recently in clinical trials
(Warrington and Herzog, 2006; Mueller and Flotte, 2008). The
movement of the gene therapy field toward the use of rAAV
vectors in clinical trials is largely due to the demonstration of
long-term transgene expression in animal models with little
associated toxicity and good overall safety profiles in humans
(Snyder and Flotte, 2002; Moss et al., 2004; Warrington and
Herzog, 2006; Maguire et al., 2008; Mueller and Flotte, 2008;
Brantly et al., 2009). Most of the historic data involve rAAV
serotype 2 vectors, but vector systems based on other AAV
serotypes with more efficient gene delivery profiles in specific
tissues are currently in human trials (Brantly et al., 2009;
Nienhuis, 2009) and their use will likely increase.
A major problem associated with the body of data to date
has been the inability to normalize vector doses administered
by different investigators to animals and humans. Thus,
there is a need for a reference standard that is recognized by
the rAAV research community and that is used to normalize
laboratory-specific internal reference standards and test
vector titers related to common reference standard units.
This need is not new to the field of gene therapy and has
previously been addressed for adenoviral vectors. The
Adenovirus Reference Material Working Group (ARMWG)
developed and characterized the adenovirus reference ma-
terial (ARM) for the purpose of normalizing titers and
doses of gene therapy vectors based on adenovirus type 5
(Hutchins, 2002). Following this example, the U.S. Food and
Drug Administration (FDA) and the National Institutes of
Health (NIH) Recombinant DNA Advisory Committee
(RAC), together with the support of the National Gene
Vector Laboratory (NGVL), a program of the NIH National
Center for Research Resources (NCRR), encouraged aca-
demic and industry scientists within the AAV commu-
nity to form an AAV Reference Standard Working Group
(AAVRSWG) charged with the development a high-quality
rAAV reference standard material (Snyder and Flotte, 2002).
The AAVRSWG is a volunteer organization and comprises
members from both industry and universities in nine dif-
ferent countries, and the International Society for BioProcess
Technology (www.ISBioTech.org), under the guidance of the
FDA and NIH (Moullier and Snyder, 2008; Potter et al., 2008).
Although new serotypes of AAV are currently emerging as
efficient gene delivery vectors, the AAVRSWG decided that
the first AAV reference standard material should be based on
the prototypical AAV serotype 2 because this is by far the
best characterized serotype. The approach used in the de-
velopment of this reference standard lays the groundwork
for the development of reference standard materials based
on other serotypes. Indeed, a second AAVRSWG has been
formed for the development of an AAV8 reference material
(Moullier and Snyder, 2008).
The AAV2RSWG recognized that the rAAV2 reference
standard material (rAAV2 RSM) must be supplied in suffi-
cient quantity to each requestor for use in all necessary tests
at each location, be of high quality, and remain stable for an
extended period of time. The group drew up guidelines for
the production and purification of the rAAV2 RSM, which
were carried out at the Vector Core of the University of
Florida’s Powell Gene Therapy Center (Gainesville, FL)
(Potter et al., 2008). The production process involved
cotransfection of batches of ten 10-layer Cell Factories con-
taining HEK293 cells with an AAV2 genome/eGFP trans-
gene plasmid and a second plasmid encoding the AAV2
capsid proteins and necessary helper functions. The trans-
fected cells were harvested and the vector was purified by
sequential rounds of column chromatography. A Quality
Control subcommittee of the AAV2RSWG was formed for
the purpose of characterizing the rAAV2 RSM. In consulta-
tion with members of the AAV2RSWG, the committee
selected the following characterization assays: (1) capsid titer
by A20 enzyme-linked immunosorbent assay (ELISA; Pro-
gen Biotechnik, Heidelberg, Germany); (2) vector genome
titer by quantitative polymerase chain reaction (qPCR); (3)
infectious titer by median tissue culture infective dose
(TCID50) with qPCR readout and by transduction (green
fluorescent protein [GFP] readout); and (4) purity and capsid
identification by sodium dodecyl sulfate–polyacrylamide gel
electrophoresis (SDS–PAGE).
The AAV2 RSM was distributed worldwide to 16 labora-
tories that volunteered to conduct one or more of the char-
acterization assays. Testing proceeded from July 2008 to
March 2009, at which point the quantitative data were col-
lated and statistically analyzed to determine mean titer and
confidence intervals. Preliminary analysis showed significant
variance and nonnormal data distribution with all of the
assays except for particle titer determination. The variance
was observed despite providing a standardized protocol and
reagents to the testing group and highlights the need within
the AAV community for a reference standard with which
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assay titers can be normalized. Using statistical transforma-
tion to better approximate normal distributions and model-
ing to offset the lack of independence of duplicate assays
within an institution, appropriate estimations of the mean
titers and confidence intervals have been determined.
Materials and Methods
Reference standard material production
Production and purification of the rAAV2 RSM were
carried out at the Vector Core of the University of Florida’s
Powell Gene Therapy Center between February 2006 and
January 2007. The production process has been described in
detail elsewhere (Potter et al., 2008) and is briefly summa-
rized here. Production was initiated by cotransfection of
HEK293 cells in ten 10-layer Nunc Cell Factories (Thermo
Fisher Scientific, Waltham, MA) with plasmid pTR-UF-11,
containing the vector genome and eGFP expression cassette
(Burger et al., 2004), and the pDG-KanR helper plasmid, a
kanamycin-resistant version of pDG (Grimm et al., 1998) at a
1:1 molar ratio, using a calcium phosphate precipitation
method. After a 60-hr incubation at 378C, 5% CO2, trans-
fected cells were washed with phosphate-buffered saline
(PBS) and harvested in PBS containing 5 mM EDTA. Samples
of cells were combined with spent tissue culture medium
and tested for mycoplasma and in vitro adventitious agents.
Cells were collected by centrifugation and stored at 208C
until purified. For vector purification, cells were thawed,
lysed with 0.5% sodium deoxycholate, treated with Benzo-
nase (Merck, Darmstadt, Germany), and then disrupted by
microfluidization. Virions were then purified by STREAM-
LINE (GE Healthcare Life Sciences, Piscataway, NJ) heparin
affinity chromatography. Peak fractions were pooled and
applied to a Phenyl Sepharose (GE Healthcare Life Sciences)
chromatography column. The flow-through collected from
this second purification step was purified and concentrated
by sulfopropyl cation-exchange chromatography. Vector
was eluted with 5–10 ml of 135 mM NaCl in PBS (equivalent
to 285 mM ionic strength) and stored at 808C. Eighteen
batches were prepared and pooled. The purified bulk was
diluted to *21011 vector genomes (VG)/ml with 135 mM
NaCl in PBS, and sterile filtered into two 1.3-liter portions.
This filtered formulated bulk was stored frozen (–808C) until
vialed. One of the 1.3-liter portions of the bulk was thawed
and refiltered, and 0.5 ml was dispensed into 2087 vials at the
American Type Culture Collection (ATCC, Manassas, VA) to
produce VR-1616, the rAAV2 RSM.
Predistribution testing
Mycoplasma. Mycoplasma testing of the production
culture cell harvest and of the filtered formulated bulk pu-
rified material was performed at a contract testing laboratory
(WuXi AppTec, Shanghai, China). For the cell harvest ma-
terial, medium and supernatant from each production batch
were sampled and pooled for testing. A total of 1107 cells in
15 ml of production culture supernatant was tested accord-
ing to Good Laboratory Practice (GLP), using the ‘‘Points to
Consider’’ assay described by the FDA Center for Biologics
Evaluation and Research (CBER/FDA, 1993). This assay
detects the presence of mycoplasma by both indirect (cell
culture) and direct (broth and agar) assays. The test article
was incubated with monkey kidney cells, stained with a
DNA-binding fluorochrome (Hoechst stain), and evaluated
microscopically by epifluorescence. Agar and broth flasks
were inoculated with test article and incubated anaerobically
and aerobically, respectively. Broths were subcultured onto
agar plates on days 3, 7, and 14 days postinoculation. All
plates were examined no sooner than 14 days postinocula-
tion. Purified bulk rAAV2 RSM was tested by a modification
of the ‘‘Points to Consider’’ assay, in which three cycles of
inoculation and incubation on Vero cells precede the assay to
allow amplification of mycoplasma. Both harvested material
and purified bulk material were also tested, using a PCR
assay directed against the 16S rRNA gene of various myco-
plasma species (WuXi AppTec).
Bioburden. The presence of aerobes, fungi, spores, and
anaerobes in the purified bulk material was quantified by
plating on various media under specific incubation condi-
tions (WuXi AppTec). The sensitivity of this assay is <5
colony-forming units (CFU)/ml.
Sterility. The vialed rAAV2 RSM (cat. no. VR-1616;
ATCC) was tested for sterility at the Indiana University
Vector Production Facility (Indianapolis, IN) according to
GLP guidelines. The presence of aerobes, anaerobes, and
fungi was tested by direct inoculation of thioglycolate broth,
Trypticase soy broth, and Sabouraud dextrose agar and in-
cubation for 14 days at the appropriate temperature. Nega-
tive and positive (Bacillus subtilis, Candida albicans, and
Bacteroides vulgatus) controls were included.
Endotoxin. The vialed rAAV2 RSM was also tested for
endotoxin at the Indiana University Vector Production Fa-
cility according to GLP guidelines and using the Limulus
amebocyte lysate gel-clotting assay. Test samples were as-
sayed in duplicate and diluted 2-fold with water. The test
reagent (100ml) was added to the rAAV2 RSM dilution and
incubated at 378C for 60 min, and the tube was examined for
the presence of a gel clot. Negative, positive, and spiked
controls were included. The sensitivity of the assay was 0.06
endotoxin unit (EU)/ml.
Previaling stability study. An rAAV2-GFP vector prepa-
ration at 21011 VG/ml, in the same formulation as the
rAAV2 RSM (PBSþ 135 mM NaCl), was placed in polypro-
pylene and glass vials (not siliconized) at 0.5 ml per vial.
Vials of each type were stored at both temperatures. Vials
held at room temperature were assayed for infectious titer
after 1 hr, 1 day, 3 days, and 7 days; vials stored at 808C
were assayed for infectious titer at 1 hr, 1 day, 14 days, 35
days, and 124 days (Potter et al., 2008).
RSM handling stability study. The rAAV2 RSM was
thawed on ice and aliquoted into siliconized plastic vials.
Aliquots were either tested immediately for transducing
titer, infectious titer, and vector genome titer or stored at 48C
or 808C for 3 days and then tested.
rAAV2 RSM handling. For AAV2 RSM characterization,
each testing laboratory received two vials from the ATCC on
dry ice. On receipt both vials were stored frozen at 708C to
908C. One vial was thawed at room temperature while
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mixing gently and then kept on wet ice. Within 1 hr
of thawing, the infectious titer and transducing titer as-
says were conducted. The remainder of the thawed vial
was stored at 48C and mixed gently on use. Within 5 days
of vial thaw, the particle titer, vector genome titer, and
purity/identity assays were performed. These steps were
repeated for the second vial, starting on a different calen-
dar day.
rAAV2 RSM characterization assays
Brief descriptions of each characterization assay follow.
For those wishing to reproduce these assays, detailed pro-
tocols can be found at the links specified below or may be
requested directly from M. Lock or R. Snyder.
Particle titer. Particle concentration was determined by
each laboratory, using four separate dilution series from a
single vial in the Progen AAV2 titration ELISA (cat. no.
PRATV; Progen Biotechnik), by comparison with a standard
curve prepared from a previously titered rAAV2 prepara-
tion. See the protocol posted at http://www.isbiotech.org/
ReferenceMaterials/pdfs/AAV2_capsid_titer_assay_V2.pdf
Vector genome titer. Vector genome concentration was
determined in duplicate, testing one replicate from each of
two vials, by quantitative PCR of serial dilutions of rAAV2
RSM against a standard curve of plasmid pTR-UF-11 (MBA-
331; ATCC) (Burger et al., 2004) See the protocol posted at
http://www.isbiotech.org/ReferenceMaterials/pdfs/AAV2_
RSS_genome_copy_titration_QPCR.pdf
Transducing titer. Serial 10-fold dilutions of rAAV2 RSM
were made on HeLaRC32 cells (CRL-2972; ATCC) (Chadeuf
et al., 2000) and coinfected with adenovirus type 5 (VR-1516;
ATCC). Fluorescence microscopy was used to count GFP-
expressing cells at 72 hr postinfection. See the protocol posted
at http://www.isbiotech.org/ReferenceMaterials/pdfs/AAV2_
RSS_Infectious_titer_assays_V2.pdf
Infectious titer. Serial 10-fold dilutions of an rAAV2 ref-
erence standard stock (RSS) were made on HeLaRC32 cells
(CRL-2972; ATCC) and coinfected with adenovirus type 5
(VR-1516; ATCC). Seventy-two hours postinfection total cell
DNA was extracted and analyzed for vector genome copies
by qPCR. Input vector genomes were subtracted and TCID50
titers were calculated according to the method of Kärber
(Kärber, 1931). See the protocol posted at http://www
.isbiotech.org/ReferenceMaterials/pdfs/AAV2_RSS_Infectious_
titer_assays_V2.pdf
Purity and identity. The purity and identity of the rAAV2
RSM were evaluated by SDS–PAGE, using SYPRO ruby
(Invitrogen, Carlsbad, CA) or silver staining (SilverXpress;
Invitrogen). The AAV2 VP1, VP2, and VP3 capsid protein
bands were evaluated for their stoichiometry and size. Purity
relative to nonvector impurities visible on stained gels was
determined. Vector identity was verified by observation of
the electrophoretic banding pattern expected for AAV2 and




rAAV2 RSM production and predistribution testing
The goal of the AAV2RSWG manufacturing subcommittee
was to make a single lot of an rAAV-eGFP vector with a yield
of 11015 vector genomes. Eighteen batches of ten 10-layer
cell factories containing 293 cells were transfected and the
resulting AAV vector was purified from the transfected cells
by sequential heparin affinity, hydrophobic interaction, and
cation-exchange chromatography. The final column eluates
from the 18 batches prepared were pooled for a total of 150 ml.
The genome titer of this purified bulk was assayed by dot–blot
assay and, using this method, it was determined that the
material contained 5.691014 VG (Potter et al., 2008). The pu-
rified bulks were combined, diluted to *21011 VG/ml, and
sterile filtered into two 1.3-liter portions. This filtered for-
mulated bulk was stored frozen (–808C) in anticipation of
vialing. In March 2008, one of the 1.3-liter portions of
the bulk stock was thawed, refiltered, and dispensed into 2087
vials at the ATCC to produce the rAAV2 RSM (cat. no. VR-
1616). The vials, frozen in the repository at the ATCC, are
available for distribution. The other 1.3-liter portion of the bulk
material remains frozen at the ATCC, to be dispensed at a
later date if demand warrants (Potter et al., 2008).
Before freezing, the filtered formulated bulk was sampled
(5 ml) and tested for bioburden by a contract testing labo-
ratory (WuXi AppTec). Aerobes, fungi, spores, and obligate
anaerobes all tested negative with an assay sensitivity of <5
CFU/sample. Before distribution, the vialed rAAV2 RSM
was tested under GLP guidelines for sterility (aerobes, an-
aerobes, fungi) and endotoxin at the Indiana University
Vector Production Facility. No bacterial or fungal contami-
nation was detected and endotoxin levels were less than 0.06
EU/ml. The production culture cell harvest and the filtered
purified bulk material were tested at WuXi AppTec for
mycoplasma contamination as detailed in Materials and
Methods (GLP ‘‘Points to Consider’’ assay). The harvest
material tested positive for Mycoplasma arginini (bovine ori-
gin) and the tests were valid (i.e., all controls performed).
The filtered purified bulk material was tested for myco-
plasma, using a modified assay with increased sensitivity. In
this test, a sample of the bulk material was passaged three
times on Vero cells before performing the GLP ‘‘Points to
Consider’’ assay. The bulk material tested negative for my-
coplasma whereas the spike-in controls performed as ex-
pected, indicating that the assay was valid. Last, the harvest
and bulk materials were tested by PCR (WuXi AppTec) for a
16S rRNA gene region specific to various mycoplasma spe-
cies. Using this assay, the harvest was confirmed positive
and the filtered formulated bulk again tested negative, with
all controls performing as expected. Thus whereas the har-
vested cells were positive for mycoplasma, the purified bulk
was negative for viable mycoplasma and no mycoplasma
DNA was detected, so it was concluded that the purification
process likely separated and/or inactivated the contaminat-
ing mycoplasma present in the harvest material (Potter et al.,
2008).
Beta testing
The AAV2RSWG Quality Control subcommittee was
formed for the purpose of characterizing the rAAV2 RSM.
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Decisions regarding the characterization assays required
were made in consultation with the AAV2RSWG, and
members were invited to submit their assay protocols. These
protocols were reviewed and a lead protocol was chosen for
each assay. The assays chosen included (1) confirmation of
the serotype and capsid particle titer by A20 ELISA (Progen
Biotechnik); (2) determination of vector genome titer by
qPCR; (3) determination of infectious titer by median tissue
culture infective dose (TCID50) with qPCR readout and by
transduction (GFP readout); (4) evaluation of the purity,
capsid subunit stoichiometry, and chemical integrity of the
capsid by SDS–PAGE.
During the protocol selection process it was realized that
the highest level of assay reproducibility in the various
testing laboratories could be ensured only if certain reagents
were provided along with the rAAV2 RSM. The reagents,
which are now available from the ATCC, include a cell line
expressing the AAV2 rep and cap genes (HeLa32; kindly
provided by P. Moullier, INSERM UMR649 Nantes, France),
a concentrated adenovirus helper virus (the adenovirus type
5 reference standard material, ARM) (VR-1516; ATCC) for
the transduction and infectivity assays, and the pTR-UF-11
vector plasmid (kindly provided by S. Zolotukhin, Powell
Gene Therapy Center and Division of Cellular and Molecular
Therapy, Department of Pediatrics, University of Florida,
Gainesville, FL) used to manufacture the AAV2 RSM viral
vector. For both genome titer and infectious titer assays, a
qPCR primer–probe set directed to the simian virus 40
(SV40) poly(A) sequence and a dilution series specific to the
RSM were selected. For the purity and identity assay, com-
mercially available assay reagents with the highest sensitiv-
ity were suggested. Using these reagents, the modified assay
protocols were beta tested at the University of Pennsylvania
Gene Therapy Program against both in-house standards
(AAV2.CMV.eGFP and AAV2.CMV.lacZ) and the rAAV2
RSM itself. The genome, infectious, and transduction titers of
the in-house standards correlated well with the titers previ-
ously established by in-house assays (see Table 2; and data
not shown) and vector genome-to-infectious or transduction
unit ratios were similar to those published elsewhere (Sal-
vetti et al., 1998; Zolotukhin et al., 1999; Zen et al., 2004).
Repeating the beta testing with the rAAV2 RSM allowed
appropriate dilution ranges to be established for several of
the characterization assays. The finalized protocols were
posted at the International Society for BioProcess Technology
website (www.ISBioTech.org) and the HeLaRC32 cells (CRL-
2972; ATCC), pTR-UF-11 plasmid (MBA-331; ATCC), and
ARM (VR-1516; ATCC) assay reagents were made available
through the ATCC. The rAAV2 RSM (VR-1616; ATCC) was
distributed along with the required reagents and handling
instructions to 16 laboratories worldwide (Table 1) that vol-
unteered to conduct one or more of the characterization
assays.
Before filling the rAAV2 RSM, a study was conducted
with a different lot of rAAV2-GFP vector in the same for-
mulation to evaluate the short-term stability of the vector at
room temperature (the filling condition) and at 808C (the
storage condition). Vials were filled with the beta test vector
and held at the test temperatures for the time periods indi-
cated (see Materials and Methods) and were then assayed for
infectious titer. In all scenarios, a 30–40% drop was observed
between the initial titer and the average of all samples taken
during the time course and it was assumed that this loss
likely indicated absorption to the container surfaces at the
low vector concentration (Potter et al., 2008), because these
containers were not siliconized. After filling the rAAV2 RSM,
a limited study was also conducted to evaluate the stability
of the rAAV2 RSM after post-thaw storage at 48C, and after
refreezing at 808C. The purpose of the study was to de-
termine the appropriate conditions for handling of the RSM
once received by the testing laboratory. Transduction titers
fell 35 and 56% after storage or refreezing at 48C and 808C,
respectively, and infectious titer fell 78 and 63%, respectively
Table 1. rAAV2 Reference Standard Material
Testing Laboratories
University of Naples Federico II, Italy
University of North Carolina Vector Laboratories, USA
Universitat Autònoma de Barcelona, Spain
Research Institute at Nationwide Children’s Hospital, USA
University of Florida, USA
Laboratoire de Thérapie Génique, France
Généthon, France
Applied Genetic Technologies, USA
International Center for Genetic Engineering and
Biotechnology (ICGEB), Italy
German Cancer Research Center (DKFZ), Germany
University of Pennsylvania, USA
Jichi Medical University, Japan
Sangamo BioSciences, USA
Université Libre de Bruxelles, Belgium
Amsterdam Molecular Therapeutics, The Netherlands
Children’s Hospital of Philadelphia, USA
Table 2. Qualification of Reference Standard Material (RSM) Testing Methods Using In-House
Standards and Beta Testing of rAAV2 RSM Under Various Storage Conditions
In-house standards rAAV2 RSM
AAV2.CMVe.GFP AAV2.CB.lacZ At thaw 48Ca 808Ca
Transducing titer (GFU/ml) 1.421010 NA 1.89109 1.23109 8.38108
Infectious titer (TCID50 IU/ml) 6.961010 2.421011 1.651010 3.56109 6.23109
Physical titer (vector genomes/ml) 4.531012 2.151012 3.391010 3.391010 3.411010
Vector genomes: infectious units 65 8.87 2.05 9.53 5.39
Vector genomes: transducing units 319 NA 17.90 27.50 40.70
Abbreviations: GFU, GFP (green fluorescent protein) forming units; NA, not available; TCID50, median tissue culture infective dose.
aAssayed 3 days postthawing, after storage at the indicated temperature.
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(Table 2). Conversely, no change was observed in the vector
genome titers under the various storage conditions. These
results indicated that the postthaw storage conditions were
adversely affecting the potency of the rAAV2 RSM and that
this decrease was not due to absorption to the siliconized
aliquot vials used in this study, because the vector genome
titer was unchanged. On the basis of these data the decision
was made to test two separate aliquots of the RSM and to
determine transducing and infectious titers within 1 hr of
thawing a vial.
rAAV2 RSM characterization
The characterization phase of the rAAV2 RSM proceeded
from July 2008 to March 2009. On receipt, the RSM was
evaluated by the 16 testing laboratories according to the
posted protocols, and data were recorded on the assay
worksheets provided, which contained the necessary calcu-
lations for titer determination. Fifteen laboratories performed
the particle titer assay (31 replicates), 16 laboratories per-
formed the genome titer assay (36 replicates), 10 laboratories
performed the infectious titer assay (23 replicates), and 12
laboratories performed the transducing titer assay (19 repli-
cates). In some cases (four of the tests), substantial experi-
mental deviation from the posted protocols was noted and
these data have been omitted from the statistical analyses.
The raw data that emerged from the testing laboratories
for the four quantitative titer assays (Table 3) was statistically
analyzed to determine true mean titer values and confidence
intervals. The distribution was first visualized as histograms
(Fig. 1), and it was noted that with the possible exception of
the particle titer results, the data do not appear to be nor-












A 1 1.081012 4.681010 1.27109
2 1.261012 8.771010 1.26109
B 1 8.251011 7.031010 3.63108 6.32109
2 8.281011 7.581010 1.00108 1.36109
3 9.391010 7.15107 2.00109
C 1 7.701011 8.601010 9.80106
2 6.051011 4.191010
D 1 8.801011 1.011010 1.70109 1.021010
2 7.831011 3.711010 2.77109 6.96109
E 1 1.161012 1.581010
2 1.041012 1.141010
3 1.611010
F 1 1.661012 2.171010 6.60108
2 1.011012 2.121010 5.70108
G 1 1.901012 1.131010 4.02108 3.23109
2 9.391011 1.301010 2.67109
H 1 2.041010
2 2.131010
I 1 8.561011 5.931010 2.20107
2 7.081011 6.101010 2.95107
J 1 1.241012 3.391010 1.89109 1.651010
2 1.071012 4.491010 1.22109 2.421010
K 1 5.291011 3.721010 2.01108
2 7.751011 3.621010 2.04108
L 1 8.131011 1.31109 5.96108 1.50109
2 4.991011 1.631010 6.48108 6.96108
M 1 1.111011 1.161010 8.88108 2.00109
2 1.251011 1.531010 4.52108 1.50109
N 1 3.931011 1.471010 3.82108 2.001010
2 5.591011 7.63109 2.62108 7.66109
3 9.581011 4.24109 2.40109
O 1 1.061012 6.041010
2 1.091012 1.271011
P 1 8.021011 4.201010 7.66109
2 7.741011 5.101010 6.96109
3 4.821010 9.28109
Mean 9.431011 3.821010 6.94108 7.00109
Standard deviation 3.191011 2.971010 7.03108 6.70109
aFour replicate test results were omitted because of documented experimental deviation from the posted protocols.
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mally distributed. Because valid estimation of the mean and
confidence interval relies on an underlying normal distri-
bution, it was clear that some form of transformation was
warranted. Common statistical transformation methods
employed are square root, natural log, and log base 10.
Means and intervals are calculated on the transformed data
and the results are then back-transformed to the original
measurement scale; the data for each assay were processed in
this way, using all three transformations. Analysis of the
mean and median (for normally distributed data these two
values are the same) and skewness and kurtosis estimates
confirmed that the transformations were performing as ex-
pected (data not shown). Figure 2 shows the results of the
most successful transformations for each assay as quantile–
quantile plots. In this analysis the quantiles (i.e., 5%, 10%,
etc.) obtained from the transformed data are compared with
the quantiles that would be expected for a normal distribu-
tion. A line that extends through the 25th and 75th quantile is
shown on the plots and the nearer the points are to this line,
the more normal the data distribution. With the exception of
two extreme points, the capsid particle titer assay data ap-
peared normally distributed without the need for transfor-
mation. For the vector genome titer and the transduction
titer, square root transformation appeared to approximate
normal distribution and seemed warranted. For the infec-
tious titer, a log base 10 transformation appeared the
most appropriate. The transformed data are summarized in
Table 4. For each assay, 2 and 3 standard deviation limits
were calculated corresponding to nominal 95 and 99.7%
confidence bounds on individual values. Any test result
lying outside of the 3 standard deviations was considered to
be an outlier. Using this criterion only a single test result
(from the particle titer assay) was determined to be an outlier
and was removed from the analysis; the values reported in
Table 4 exclude this data point.
An assumption we have made when calculating the mean
values and confidence intervals is that each test result is in-
dependent of another; however, this assumption does not
take into account that all institutions submitted duplicate
(and in some cases triplicate) test results for the assays. To
assess the degree of correlation between the two duplicate
samples, Pearson coefficients were determined. These esti-
mates ranged from 0.57 to 0.84 for the four assays (where a
value of 1 indicates a perfect correlation). The results indicate
that there is a significant correlation within institution and
that the assumption that each result is independent is vio-
lated. To account for this correlation, the transformed data
were modeled, using a linear random effect modeling ap-
proach (Littell et al., 2006). This allows for a unique compo-
nent associated with each institution to be included in the
model, under the assumption that these institutional random
effects have a mean of zero. When the correlation within an
FIG. 1. Histograms displaying the distributions of (a) particle titer (pt/ml), (b) vector genome titer (VG/ml), (c) transducing
titer (GFU/ml), and (d) infectious titer (IU/ml).
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institution is accounted for, the precision of the mean esti-
mate as illustrated by the width of the 95% confidence in-
terval is decreased (Table 5). Taking the transformed,
modeled data as the true estimate of the mean, we have
arrived at the following determinations for the rAAV2 RSM:
the mean particle titer is 9.181011 particles/ml with 95%
confidence that the true value lies in the range of 7.891011
to 1.051012 particles/ml; the mean vector genome titer is
3.281010 vector genomes/ml with 95% confidence that the
true value lies in the range of 2.701010 to 4.751010 vector
genomes/ml; the mean transducing titer is 5.09108 trans-
ducing units/ml with 95% confidence that the true value lies
in the range of 2.00108 to 9.60108 transducing units/ml;
and the mean infectious titer is 4.37109 TCID50 IU/ml with
FIG. 2. Quantile–quantile plots displaying sample versus normal quantiles of (a) particles per milliliter, (b) square root of
vector genomes per milliliter, (c) square root of transducing units per milliliter, and (d) log10 infectious units per milliliter.
Lines pass through the 25th and 75th quantiles.










the mean  2 SD  3 SD
Particles/ml
(ELISA)












Log10 4.49109 2.75109 7.29109 5.94108–3.391010 2.16108–9.311010
aUsed to better qualify the assumption of normal distribution for the purpose of determining distributional values.
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95% confidence that the true value lies in the range of
2.06109 to 9.26109 TCID50 IU/ml. The mean vector ge-
nome titer of 3.281010 VG/ml is almost 1 log lower than the
titer of 21011 VG/ml assessed for the diluted purified bulk
harvest before vialing. The discrepancy between the bulk
material and final fill may be due to loss of vector after fil-
tering of the bulk product, to the different assay methods
used for the titering (dot–blot vs. qPCR), or a combination of
both. The bulk vector was titered at the University of Florida,
using the method of dot–blot hybridization to determine the
appropriate formulation volume for the final fill. It is possi-
ble that the loss, if any, occurred during the final filtration
and filling of the dilute reference standard material at the
ATCC (diluted nearly 1000 times relative to preparations
that are used preclinically or clinically). The product that was
vialed and frozen constitutes the reference standard material
that was characterized, and that is available to the community.
Some important properties of the rAAV2 RSM are indi-
cated by the ratios of the titers (Table 6). The vector genome-
to-infectious titer (VG:IU) ratio is often used as a measure of
the relative infectivity of the vector, with lower ratios re-
flecting more infectious preparations. The rAAV2 RSM
VG:IU ratio is 7.5, which indicates that the RSM has retained
infectivity. The vector genome-to-transduction titer (VG:TU)
ratio is 8.6-fold higher than the VG:IU ratio, and this result
reflects the different sensitivities of the infectivity and
transduction (measuring infectivity and gene expression)
assays. Another ratio that is often used is the particle-to-
vector genome titer ratio (P:VG). This ratio indicates the ratio
of total particles, including both empty and full, to those
particles containing the vector genome. The P:VG ratio ob-
tained for the rAAV2 RSM is 28 and indicates a large excess
of empty particles. This finding is consistent with the fact
that the chromatographic purification process used in the
production of the rAAV2 RSM was not designed to separate
empty and full particles. One concern is that empty particles
may have adversely affected the performance of the rAAV2
RSM in transduction and infectivity assays. However, during
beta testing, two triple-transfected CsCl-purified lots (one
each of AAV2.CMV.eGFP and AAV2.CMV.lacZ) were tes-
ted, using the RSS characterization methods: vector genome
(qPCR), TCID50, and where applicable eGFP transduction
titering. Because these were CsCl-purified preparations the
empty capsid content is lower than in preparations purified
by chromatography. The VG:TCID50 IU ratios and VG:TU
ratios were similar or greater than those obtained for the
reference standard (Tables 2 and 6). Similarly, the VG:TCID50
IU ratios and VG:TU ratios of the reference standard (Table
6) are similar to those reported in the literature for other
AAV2 vectors (Salvetti et al., 1998; Zolotukhin et al., 1999;
Zen et al., 2004).
The purity of the rAAV2 RSM was assessed and the capsid
identity confirmed by SDS–PAGE analysis. The RSM was
examined under both reducing and nonreducing conditions,
using SYPRO ruby and silver stains (Fig. 3). Under reducing
conditions all proteins including the denatured AAV2 cap-
sids are expected to enter the gel and impurities would be
detected as protein bands other than the capsid proteins VP1,
VP2, and VP3. Under nonreducing conditions the capsid
would remain intact and would not be expected to enter the
resolving gel, whereas impurities would enter the gel; pro-
teins that previously comigrated with the capsid proteins on
reducing gels would thus be detected. Silver nitrate staining
was included because it is capable of detecting DNA, lipid,
and carbohydrate impurities as well as nanogram levels of
protein (Weiss et al., 2009). SYPRO ruby is a protein-specific
fluorescent dye that has a sensitivity close to that of silver
stain (Rabilloud et al., 2001; Weiss et al., 2009). In each case
the rAAV2 RSM was analyzed alongside an internal labo-
ratory standard AAV2 vector. The consensus data from the
11 testing laboratories that carried out the purity/identity
test estimated that the rAAV2 RSM was greater than 94%
pure and confirmed that VP1, VP2, and VP3 comigrated with
the AAV2 capsid proteins of the internal vector standards
(Fig. 3; and data not shown).
Discussion
As rAAV vectors more frequently head toward the clinic
for gene therapy trials, there is an increasing need to share
pharmacokinetic, toxicologic, and efficacy data. This need is










the mean  2 SD  3 SD
Particles/ml (ELISA) Untransformed 9.181011 7.891011 1.051012 3.731011–1.451012 1.041011–1.781012
Vector genomes/ml
(qPCR)
Square root 3.281010 2.701010 4.751010 9.00108–1.041011 0–1.661011
Transducing units/ml
(green cells)
Square root 5.09108 2.00108 9.60108 0–2.47109 0–4.00109
Infectious units/ml
(TCID50)
Log10 4.37109 2.06109 9.26109 5.15108–3.711010 1.77108–1.081011
aUsed to better qualify the assumption of normal distribution for the purpose of determining distributional values.
Table 6. rAAV2 Reference Standard
Material Titer Ratios
Ratio
Particles: vector genomesa 27.99
Vector genomes: infectious units 7.51
Vector genomes: transducing units 64.44
Particles: infectious units 210.07
aA measure of the ratio of total particles to full particles.
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currently confounded by the lack of standardization of crit-
ical vector parameters such as vector strength and potency.
The standardization issues arise because different assays or
different protocols for the same assay are often used by in-
dividual investigators to measure an identical vector prop-
erty. The introduction of a widely accepted rAAV reference
standard would allow laboratories to characterize AAV
vectors in terms of common units, therefore facilitating
comparison of doses determined by disparate assays and
permitting safe and effective dosage at equivalent levels.
Furthermore, efficacy and toxicology data reported in the
literature could be used as a guide for initial dosing in ani-
mals and humans.
Here we have described the characterization of the first
rAAV reference standard, an AAV serotype 2 vector. The
goal of the AAV2RSWG was to provide a stable, high-
quality, highly characterized RSM that would be both ac-
cepted and easily accessed by the AAV research community.
As pointed out by FDA officials at the beginning of the effort,
a reference standard material does not need to be pure or the
‘‘best,’’ it just needs to be well characterized. Furthermore,
there are many examples of viral reference standard mate-
rials from the World Health Organization (WHO, Geneva,
Switzerland) and the National Institute for Biological Stan-
dards and Control (NIBSC, Potters Bar, UK) that are not pure
(e.g., poliovirus and hepatitis B virus references). Although
the rAAV2 RSM was made in a research vector core and not
at a current Good Manufacturing Procedure (cGMP) facility,
it was extensively tested for adventitious agents and con-
taminants. The final rAAV2 RSM product was negative for
adventitious agents in all tests to which it was subjected,
although the harvest material was exposed to mycoplasma
that was cleared and/or inactivated in the purification pro-
cess, because the purified bulk tested negative for viable
mycoplasma and mycoplasma DNA (Potter et al., 2008).
Because the rAAV2 RSM is a reference standard to be used in
research and quality control (QC) laboratories and is not
intended for use in humans, the AAV2RSWG recommended
that filling, banking, and characterization proceed. A sum-
mary of the mycoplasma testing will be included on the
FIG. 3. The rAAV2 RSM was run on
SDS–polyacrylamide gels under both re-
ducing and native conditions and then
stained with (a) SYPRO ruby or (b) silver
stain. An in-house rAAV2 standard was
run as a positive control and buffer as a
negative control. The lanes for each gel are
as follows: (1) benchmark ladder (un-
stained or prestained)—reduced; (2) neg-
ative control—reduced; (3) AAV reference
material—reduced; (5) positive control—
reduced; (6) benchmark ladder (unstained
or prestained)—native; (7) negative
control—native; (8) AAV reference
material—native; (10) positive control—
native.
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product information sheet supplied with each shipment of
the rAAV2 RSM, stating that the reference standard has been
exposed to mycoplasma, but is mycoplasma-free. Thus, in-
stitutions and companies requesting the rAAV2 RSM will be
fully informed and can decide if they want to bring it into
their QC laboratories. The reference material is intended to
be restricted to QC laboratories, isolated from production
suites. In addition, it is envisioned that internal reference
standards will be calibrated against the AAV2 RSM one time
and then used on a routine basis for product-specific testing.
The short-term stability testing performed on the surro-
gate AAV2-GFP vector as well as on the final vialed rAAV2
RSM material suggested that some loss of vector potency
was occurring on storage. Initially this loss was assumed to
be due to absorption to the surfaces of the vial as was seen in
the previous study using vials that were not siliconized
(Potter et al., 2008); however, when vector genomes were
assayed no corresponding loss was seen when using sili-
conized vials (Table 2). One explanation for the loss of po-
tency observed may be the omission of a stabilizing excipient
in the final formulation (Croyle et al., 2001; Wright et al.,
2003). The beta test stability results influenced the way the
rAAV2 RSM was handled during the testing phase; aliquots
were thawed only once and transduction and infectivity as-
says were performed within 1 hr of this thaw. Regarding
future use of the reference material for potency assays, it
would seem essential that a similar protocol be followed
when normalizing internal reference standards against the
rAAV2 RSM. For physical titer assays such as particle and
vector genome assays, storage and refreezing are permissi-
ble. Plans for assessing the long-term stability of the rAAV2
RSM by yearly testing for capsid protein integrity, infectious
titer, transducing titer, and vector genome titer are in place.
Data will be reported by the AAV2RSWG through the Re-
ference Standards section of the International Society for
BioProcess Technology website (www.ISBioTech.org).
The characterization phase of the rAAV2 RSM project
successfully fulfilled the goals of the AAV2RSWG by ob-
taining mean titers and 95% confidence intervals from a large
number of representative assays performed by numerous
test centers. The tightest confidence intervals were obtained
for the nonbiological assays (particle titer and vector genome
titer) whereas the biological assays (infectious titer and
transduction titer) gave wider intervals (Table 5). This pat-
tern might be expected because the biological assays are in-
herently more variable. The tight confidence interval
observed for the vector genome titer is relevant because this
titer has been used exclusively in dosing regimens and a high
degree of precision is important for the use of the rAAV2
RSM in dose standardization.
One obvious trend in the quantitative assay data was the
degree of variation between institutions for each assay (Fig. 1
and Table 3) despite the relatively tight correlation of assay
results within an institution (Table 3). This poor degree of
interlaboratory precision and accuracy was apparent even
though attempts were made to standardize the assays by
providing detailed protocols and common reagents. The
variation may be explained by the use of different reagents
(i.e., other than those provided, such as tissue culture media,
PCR primers, and PCR mixes), equipment, and/or operator
technique. This is the first time that such variation between
laboratories has been thoroughly documented and the find-
ings emphasize the need in the field for universal reference
standards. This need is especially apparent when it is con-
sidered that fundamentally dissimilar tests are often used to
measure the same parameter (e.g., qPCR and dot–blot for
vector genome titer) and that even when different laborato-
ries use the same assay, different protocols are usually fol-
lowed. For some assays the variation is not large, with the
most important measure, vector genome titer (qPCR), which
is almost exclusively used for dosing in preclinical and
clinical studies, having low variation (confidence interval of
less than 0.5 log). Despite the spread of infectious titers, the
mean value represents the best titer based on multiple rep-
licates conducted at the different sites on different test dates.
Because the rAAV2 RSM supply is limited, it is not in-
tended that it be used routinely, but rather for the calibration
of laboratory-specific internal reference standards, which can
then be run concurrently with test samples in subsequent
assays that have been validated. The initial calibration would
involve titering the RSM alongside the internal standard in
the same assay; the difference between the titer determined
in this assay and the accepted titer of the RSM would act as a
conversion factor for calculating the titer of the internal
standard in reference standard units (RSU). Once the internal
standard titer is known in reference standard units per mil-
liliter, the titer of test samples can be calculated similarly in
the same units, during subsequent assays. It is envisaged that
the RSM will be used in this way for standardizing the ge-
nome titer, particle titer, and infectious titer of AAV2 vectors.
A prerequisite for qPCR or hybridization-based vector ge-
nome/infectivity titering methods would be that the internal
AAV standard share enough genome sequence with the
rAAV2 RSM for oligonucleotide or labeled probe annealing.
Several common transcriptional elements are included in the
rAAV2 RSM genome for this purpose and many existing
internal reference standards will therefore be candidates for
calibration. If this is not the case, new internal standards will
need to be produced that harbor DNA elements in common
with the AAV2 RSM. For transducing titers, the encoded
transgene provides the basis of detection and, therefore, with
the exception of GFP-expressing vectors for preclinical
studies, these titers will generally not be amenable to stan-
dardization using the rAAV2 RSM.
Although the primary intent of the rAAV2 RSM was to
provide a reference point for AAV2 serotype vectors it is
possible that for nonbiological assays such as vector genome
titration, the rAAV2 RSM could be used for the calibration of
other AAV serotypes. Because the vector capsid is not di-
rectly involved in these types of assays, it might be argued
that there is no capsid specificity and that the capsid serotype
would not have an impact. As an example, in the vector
genome titer assay it might be assumed that different capsids
are equally susceptible to PCR heat treatment for liberation
of the vector genome. However, conditions would need to be
optimized because equal susceptibility of AAV serotypes to
heat has not been definitively demonstrated. In addition,
proteolysis is often used to liberate the vector genome and it
is known that different capsid serotypes have different sus-
ceptibilities to protease treatments (Van Vliet et al., 2006).
Similarly, serotype-independent methods of determining
particle titer (e.g., high-performance liquid chromatography,
spectrophotometry) could be calibrated, using the rAAV2
RSM, but the same assumption of capsid independence
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would apply, and for spectrophotometric measurements the
proper extinction coefficient would need to be incorporated
(Sommer et al., 2003). If data are available to demonstrate
that an assay is indeed capsid independent, then the use of
the rAAV2 RSM for other serotypes may well be acceptable,
but thorough review with the appropriate regulatory agency
is recommended. For biological assays such as infectious
titer, the paramount roles of the capsid, the requisite target cell
line, and the helper virus preclude the use of the rAAV2 RSM
to calibrate other serotypes. For these assays, investigators
must await the development of further reference standard
materials such as the AAV8 material currently under pro-
duction (Moullier and Snyder, 2008).
The rAAV2 RSM carries a single-stranded DNA vector
genome. Self-complementary AAV vector genomes, gener-
ated with a mutation within the terminal repeat (McCarty
et al., 2003), have become popular for gene transfer because
they bypass the rate-limiting genome conversion of single-
stranded to double-stranded DNA during transduction of
target cells. The rAAV2 RSM can be used to normalize
‘‘in-house’’ reference standards for both the classic single-
stranded vectors and self-complementary vectors. Because
self-complementary vectors carry double the genome com-
plement of single-stranded vectors, a simple conversion is
necessary when calculating vector genome titers for these
two vector types.
In the United States, the FDA Center for Biologics Eva-
luation and Research (CBER), Office of Cellular, Tissue, and
Gene Therapies (OCTGT), Division of Cellular and Gene
Therapies (DCGT) recommends reference materials as
benchmarking tools for qualifying and validating ‘‘in-house’’
reference standards and assays by comparison with the col-
lective data. It should be noted that it is not the intent of the
FDA to standardize assay methods across the field or to re-
quire that the values assigned to the rAAV2RSM be dupli-
cated during validation studies. Furthermore, there is no
requirement in the United States to follow rAAV2 RSM
procedures when assaying particle concentration, genome
copy number, or infectious titer. Sponsors of adeno-associated
virus-related investigational new drugs (INDs) should con-
sult with the FDA/CBER or appropriate national agency for
further guidance. The rAAV2 RSM fulfills many of the re-
quirements of a reference standard material in that it (1) is
sufficiently homogeneous and stable with respect to speci-
fied properties, (2) is established to be fit for its intended use
in measurement, (3) is accompanied by documentation, (4)
provides relevant property values that are based on multiple
measurements conducted at different locations, and (5) is
accompanied with associated measurement uncertainty.
From the outset, the vision of the AAV2RSWG for the
rAAV2 RSM was that it would represent the first step to-
ward standardization of AAV-based gene therapy dosing
and provide a blueprint for the development of reference
standards for other AAV serotypes. This vision is becoming
reality through the successful production and characteriza-
tion reported here, and with the effort to develop the AAV8
reference standard material underway. The requirement that
the reference materials be universally accepted by the AAV
community has dictated the need for a voluntary communal
effort in the production and characterization phases. Despite
the numerous drawbacks, difficulties, and delays inherent in
this type of approach, the AAV gene therapy community has
responded selflessly and with enthusiasm. It is hoped that
the ultimate success of this collaboration will inspire future
reference standard efforts and contribute to the development
and commercialization of AAV-based gene therapeutics.
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